<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>How to Stop Semaglutide the Right Way: A Step-Down Protocol — Élan Clinic</title>
  <meta name="description" content="Most people stop Ozempic or Wegovy overnight. That's the approach most likely to undo your results. An Élan Clinic physician explains the tapering protocol — what to do, what to expect, and what to watch for." />
  <link rel="canonical" href="https://elan.clinic/blog/how-to-stop-semaglutide-safely.html" />
  <link rel="icon" type="image/svg+xml" href="/favicon.svg" />

  <!-- Open Graph -->
  <meta property="og:type" content="article" />
  <meta property="og:url" content="https://elan.clinic/blog/how-to-stop-semaglutide-safely.html" />
  <meta property="og:title" content="How to Stop Semaglutide the Right Way: A Step-Down Protocol" />
  <meta property="og:description" content="Most people stop Ozempic or Wegovy overnight. That's the approach most likely to undo your results. An Élan Clinic physician explains the tapering protocol — what to do, what to expect, and what to watch for." />
  <meta property="og:locale" content="en_GB" />
  <meta property="article:published_time" content="2026-02-28" />
  <meta property="article:author" content="Dr. Ingmar Lindström" />

  <!-- Schema.org MedicalWebPage + FAQ + BreadcrumbList -->
  <script type="application/ld+json">
  {
    "@context": "https://schema.org",
    "@type": "MedicalWebPage",
    "name": "How to Stop Semaglutide the Right Way: A Step-Down Protocol",
    "headline": "How to Stop Semaglutide the Right Way: A Step-Down Protocol",
    "url": "https://elan.clinic/blog/how-to-stop-semaglutide-safely.html",
    "datePublished": "2026-02-28",
    "inLanguage": "en",
    "description": "Most people stop Ozempic or Wegovy overnight. That's the approach most likely to undo your results. An Élan Clinic physician explains the tapering protocol — what to do, what to expect, and what to watch for.",
    "about": {
      "@type": "MedicalCondition",
      "name": "Obesity"
    },
    "medicalAudience": {
      "@type": "MedicalAudience",
      "audienceType": "Patient"
    },
    "author": {
      "@type": "Person",
      "name": "Dr. Ingmar Lindström",
      "jobTitle": "Physician",
      "worksFor": {
        "@type": "MedicalClinic",
        "name": "Élan Clinic",
        "url": "https://elan.clinic"
      }
    },
    "publisher": {
      "@type": "MedicalClinic",
      "name": "Élan Clinic",
      "url": "https://elan.clinic",
      "logo": "https://elan.clinic/favicon.svg",
      "telephone": "+37252999399",
      "address": {
        "@type": "PostalAddress",
        "streetAddress": "Sepapaja 12/1",
        "addressLocality": "Tallinn",
        "postalCode": "11415",
        "addressCountry": "EE"
      }
    },
    "mainEntityOfPage": {
      "@type": "WebPage",
      "@id": "https://elan.clinic/blog/how-to-stop-semaglutide-safely.html"
    },
    "citation": [
      {
        "@type": "ScholarlyArticle",
        "name": "Weight regain after discontinuation of GLP-1 receptor agonists: a systematic review and meta-analysis",
        "author": "West et al.",
        "isPartOf": { "@type": "Periodical", "name": "BMJ" },
        "identifier": "BMJ 2026;392:e085304",
        "datePublished": "2026"
      },
      {
        "@type": "ScholarlyArticle",
        "name": "Gradual withdrawal protocols and rebound appetite in GLP-1 discontinuation",
        "author": "Winnett Specialist Group",
        "datePublished": "2025"
      }
    ]
  }
  </script>

  <script type="application/ld+json">
  {
    "@context": "https://schema.org",
    "@type": "FAQPage",
    "mainEntity": [
      {
        "@type": "Question",
        "name": "How long does it take for semaglutide to leave your system after stopping?",
        "acceptedAnswer": {
          "@type": "Answer",
          "text": "Semaglutide has a half-life of approximately one week, meaning it takes about five to seven weeks for the drug to be fully cleared from your system after the final injection. This is why the first two weeks after stopping often feel manageable — the medication is still partially active. Hunger and appetite changes typically become noticeable from weeks three to four onward."
        }
      },
      {
        "@type": "Question",
        "name": "Is it safe to stop Ozempic or Wegovy suddenly?",
        "acceptedAnswer": {
          "@type": "Answer",
          "text": "Stopping abruptly is not dangerous in the way that stopping some medications can be — there is no acute withdrawal syndrome. However, abrupt discontinuation causes a sharper, faster appetite rebound than a gradual taper, because the body has no time to recalibrate its hunger signalling systems. If you can taper gradually, it gives you a significantly better chance of protecting your weight loss results."
        }
      },
      {
        "@type": "Question",
        "name": "Can I restart semaglutide after taking a break?",
        "acceptedAnswer": {
          "@type": "Answer",
          "text": "Yes. Restarting GLP-1 therapy after a planned or unplanned break is medically appropriate and well-tolerated. The body responds similarly to re-initiation as it did to the original treatment, though dose escalation should follow the same gradual approach as the first time. An Élan Clinic consultation can help you decide whether restarting makes sense for your situation."
        }
      }
    ]
  }
  </script>

  <script type="application/ld+json">
  {
    "@context": "https://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
      {
        "@type": "ListItem",
        "position": 1,
        "name": "Home",
        "item": "https://elan.clinic/"
      },
      {
        "@type": "ListItem",
        "position": 2,
        "name": "Articles",
        "item": "https://elan.clinic/blog.html"
      },
      {
        "@type": "ListItem",
        "position": 3,
        "name": "How to Stop Semaglutide the Right Way",
        "item": "https://elan.clinic/blog/how-to-stop-semaglutide-safely.html"
      }
    ]
  }
  </script>

  <!-- Google Fonts -->
  <link rel="preconnect" href="https://fonts.googleapis.com" />
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin />
  <link href="https://fonts.googleapis.com/css2?family=Playfair+Display:ital,wght@0,400;0,500;0,600;0,700;1,400;1,500&family=Inter:wght@300;400;500;600&display=swap" rel="stylesheet" />

  <style>
    /* ─── Reset & Base ─────────────────────────────────────────────── */
    *, *::before, *::after { box-sizing: border-box; margin: 0; padding: 0; }

    html { scroll-behavior: smooth; font-size: 16px; }

    body {
      font-family: 'Inter', sans-serif;
      background-color: #0D1B2A;
      color: rgba(232, 228, 222, 0.55);
      line-height: 1.7;
      -webkit-font-smoothing: antialiased;
    }

    h1, h2, h3, h4 {
      font-family: 'Playfair Display', serif;
      color: #E8E4DE;
      line-height: 1.2;
      font-weight: 500;
    }

    a { color: #C5A55A; text-decoration: none; }
    a:hover { text-decoration: underline; }

    /* ─── Layout ───────────────────────────────────────────────────── */
    .container {
      width: 100%;
      max-width: 1200px;
      margin: 0 auto;
      padding: 0 24px;
    }

    /* ─── Gold Utilities ───────────────────────────────────────────── */
    .label {
      display: inline-block;
      font-family: 'Inter', sans-serif;
      font-size: 0.7rem;
      font-weight: 600;
      letter-spacing: 0.18em;
      text-transform: uppercase;
      color: #C5A55A;
      margin-bottom: 20px;
    }

    .gold-line {
      width: 48px;
      height: 2px;
      background: #C5A55A;
      margin: 28px 0;
    }

    /* ─── Nav ──────────────────────────────────────────────────────── */
    .nav {
      position: fixed;
      top: 0;
      left: 0;
      right: 0;
      z-index: 100;
      padding: 20px 24px;
      display: flex;
      align-items: center;
      justify-content: space-between;
      background: rgba(13, 27, 42, 0.92);
      backdrop-filter: blur(12px);
      border-bottom: 1px solid rgba(197, 165, 90, 0.12);
    }

    .nav__logo {
      font-family: 'Playfair Display', serif;
      font-size: 1.25rem;
      color: #E8E4DE;
      letter-spacing: 0.06em;
      text-decoration: none;
    }

    .nav__logo span { color: #C5A55A; }

    .nav__links {
      display: flex;
      align-items: center;
      gap: 32px;
      list-style: none;
    }

    .nav__links a {
      font-size: 0.78rem;
      font-weight: 500;
      letter-spacing: 0.1em;
      text-transform: uppercase;
      color: rgba(232, 228, 222, 0.65);
      text-decoration: none;
      transition: color 0.2s;
    }

    .nav__links a:hover,
    .nav__links a.active { color: #C5A55A; }

    /* ─── Breadcrumb ───────────────────────────────────────────────── */
    .breadcrumb {
      padding: 120px 0 0;
      background-color: #0D1B2A;
    }

    .breadcrumb__inner {
      display: flex;
      align-items: center;
      gap: 8px;
      flex-wrap: wrap;
    }

    .breadcrumb__item {
      font-size: 0.75rem;
      font-weight: 500;
      letter-spacing: 0.08em;
      color: rgba(232, 228, 222, 0.4);
      text-transform: uppercase;
    }

    .breadcrumb__item a {
      color: rgba(232, 228, 222, 0.4);
      text-decoration: none;
      transition: color 0.2s;
    }

    .breadcrumb__item a:hover {
      color: #C5A55A;
      text-decoration: none;
    }

    .breadcrumb__sep {
      font-size: 0.7rem;
      color: rgba(197, 165, 90, 0.4);
    }

    .breadcrumb__item--current {
      color: #C5A55A;
    }

    /* ─── Article Header ───────────────────────────────────────────── */
    .article-header {
      padding: 48px 0 64px;
      background-color: #0D1B2A;
      position: relative;
      overflow: hidden;
    }

    .article-header::before {
      content: '';
      position: absolute;
      top: -100px;
      right: -150px;
      width: 500px;
      height: 500px;
      background: radial-gradient(circle, rgba(197,165,90,0.05) 0%, transparent 70%);
      pointer-events: none;
    }

    .article-header__content {
      max-width: 780px;
    }

    .article-header h1 {
      font-size: clamp(2rem, 4.5vw, 3.2rem);
      line-height: 1.15;
      margin-bottom: 28px;
    }

    .article-meta {
      display: flex;
      align-items: center;
      flex-wrap: wrap;
      gap: 24px;
      padding-top: 24px;
      border-top: 1px solid rgba(197, 165, 90, 0.15);
    }

    .article-meta__item {
      display: flex;
      align-items: center;
      gap: 8px;
      font-size: 0.8rem;
      color: rgba(232, 228, 222, 0.5);
    }

    .article-meta__item strong {
      color: rgba(232, 228, 222, 0.75);
      font-weight: 500;
    }

    .article-meta__dot {
      width: 3px;
      height: 3px;
      border-radius: 50%;
      background: rgba(197, 165, 90, 0.4);
    }

    /* ─── Article Body ─────────────────────────────────────────────── */
    .article-body {
      padding: 0 0 100px;
      background-color: #0D1B2A;
    }

    .article-body__inner {
      max-width: 780px;
    }

    .article-body p {
      font-size: 1.05rem;
      color: rgba(232, 228, 222, 0.72);
      line-height: 1.85;
      margin-bottom: 28px;
    }

    .article-body h2 {
      font-size: clamp(1.5rem, 2.5vw, 2rem);
      margin: 56px 0 20px;
      color: #E8E4DE;
    }

    .article-body h3 {
      font-size: clamp(1.1rem, 2vw, 1.35rem);
      margin: 40px 0 16px;
      color: #E8E4DE;
    }

    .article-body strong {
      color: rgba(232, 228, 222, 0.9);
      font-weight: 600;
    }

    .article-body em {
      color: rgba(232, 228, 222, 0.65);
      font-style: italic;
    }

    .article-body hr {
      border: none;
      height: 1px;
      background: rgba(197, 165, 90, 0.15);
      margin: 48px 0;
    }

    /* ─── Pull Quote ───────────────────────────────────────────────── */
    .pull-quote {
      border-left: 3px solid #C5A55A;
      padding: 20px 32px;
      margin: 40px 0;
      background: rgba(197, 165, 90, 0.04);
    }

    .pull-quote p {
      font-family: 'Playfair Display', serif;
      font-size: 1.2rem !important;
      font-style: italic;
      color: rgba(232, 228, 222, 0.82) !important;
      line-height: 1.6 !important;
      margin: 0 !important;
    }

    /* ─── Key Stat ─────────────────────────────────────────────────── */
    .key-stat {
      background: #111D2E;
      border: 1px solid rgba(197, 165, 90, 0.18);
      padding: 32px 36px;
      margin: 40px 0;
    }

    .key-stat__number {
      font-family: 'Playfair Display', serif;
      font-size: 3rem;
      color: #C5A55A;
      line-height: 1;
      margin-bottom: 8px;
    }

    .key-stat__label {
      font-size: 0.88rem;
      color: rgba(232, 228, 222, 0.6);
      line-height: 1.5;
    }

    /* ─── Taper Table ──────────────────────────────────────────────── */
    .taper-table {
      width: 100%;
      border-collapse: collapse;
      margin: 40px 0;
      font-size: 0.9rem;
    }

    .taper-table th {
      font-family: 'Inter', sans-serif;
      font-size: 0.7rem;
      font-weight: 600;
      letter-spacing: 0.12em;
      text-transform: uppercase;
      color: #C5A55A;
      text-align: left;
      padding: 12px 16px;
      border-bottom: 1px solid rgba(197, 165, 90, 0.2);
      background: #111D2E;
    }

    .taper-table td {
      padding: 14px 16px;
      border-bottom: 1px solid rgba(197, 165, 90, 0.08);
      color: rgba(232, 228, 222, 0.7);
      vertical-align: top;
    }

    .taper-table tr:last-child td {
      border-bottom: none;
    }

    .taper-table tr:hover td {
      background: rgba(197, 165, 90, 0.03);
    }

    /* ─── Warning Box ──────────────────────────────────────────────── */
    .warning-box {
      background: rgba(197, 165, 90, 0.06);
      border: 1px solid rgba(197, 165, 90, 0.25);
      padding: 24px 28px;
      margin: 40px 0;
    }

    .warning-box__title {
      font-family: 'Inter', sans-serif;
      font-size: 0.72rem;
      font-weight: 600;
      letter-spacing: 0.14em;
      text-transform: uppercase;
      color: #C5A55A;
      margin-bottom: 12px;
    }

    .warning-box p {
      font-size: 0.9rem !important;
      color: rgba(232, 228, 222, 0.65) !important;
      line-height: 1.7 !important;
      margin: 0 !important;
    }

    /* ─── Article Sources ──────────────────────────────────────────── */
    .article-sources {
      margin-top: 60px;
      padding-top: 32px;
      border-top: 1px solid rgba(197, 165, 90, 0.12);
    }

    .article-sources p {
      font-size: 0.82rem !important;
      color: rgba(232, 228, 222, 0.38) !important;
      line-height: 1.6 !important;
      margin-bottom: 8px !important;
    }

    .article-sources .sources-label {
      font-size: 0.7rem;
      font-weight: 600;
      letter-spacing: 0.15em;
      text-transform: uppercase;
      color: #C5A55A;
      margin-bottom: 16px;
      display: block;
    }

    /* ─── Back Link ────────────────────────────────────────────────── */
    .back-link {
      display: inline-flex;
      align-items: center;
      gap: 8px;
      font-size: 0.78rem;
      font-weight: 600;
      letter-spacing: 0.1em;
      text-transform: uppercase;
      color: rgba(232, 228, 222, 0.5);
      text-decoration: none;
      transition: color 0.2s, gap 0.2s;
      margin-bottom: 60px;
    }

    .back-link:hover {
      color: #C5A55A;
      gap: 12px;
      text-decoration: none;
    }

    /* ─── Footer CTA ───────────────────────────────────────────────── */
    .footer-cta {
      background-color: #111D2E;
      border-top: 1px solid rgba(197, 165, 90, 0.12);
      text-align: center;
      padding: 100px 24px;
    }

    .footer-cta h2 {
      max-width: 620px;
      margin: 0 auto 24px;
      font-size: clamp(1.6rem, 3vw, 2.2rem);
    }

    .footer-cta__sub {
      max-width: 480px;
      margin: 0 auto 40px;
      font-size: 0.95rem;
    }

    /* ─── Button ───────────────────────────────────────────────────── */
    .btn {
      display: inline-block;
      padding: 16px 36px;
      font-family: 'Inter', sans-serif;
      font-size: 0.85rem;
      font-weight: 600;
      letter-spacing: 0.1em;
      text-transform: uppercase;
      border: 1.5px solid #C5A55A;
      color: #C5A55A;
      background: transparent;
      cursor: pointer;
      transition: background 0.2s, color 0.2s;
      text-decoration: none;
    }

    .btn:hover {
      background: #C5A55A;
      color: #0D1B2A;
      text-decoration: none;
    }

    .btn--filled {
      background: #C5A55A;
      color: #0D1B2A;
    }

    .btn--filled:hover {
      background: #d4b56a;
      color: #0D1B2A;
    }

    /* ─── Footer Legal ─────────────────────────────────────────────── */
    .footer-legal {
      background-color: #0D1B2A;
      border-top: 1px solid rgba(197, 165, 90, 0.08);
      padding: 40px 24px;
    }

    .footer-legal__inner {
      max-width: 1200px;
      margin: 0 auto;
      display: flex;
      flex-direction: column;
      gap: 8px;
    }

    .footer-legal p {
      font-size: 0.75rem;
      color: rgba(232, 228, 222, 0.3);
      line-height: 1.6;
    }

    /* ─── Responsive ───────────────────────────────────────────────── */
    @media (max-width: 768px) {
      .nav__links {
        gap: 16px;
      }

      .nav__links a {
        font-size: 0.72rem;
      }

      .breadcrumb {
        padding-top: 100px;
      }

      .article-header {
        padding: 32px 0 48px;
      }

      .article-body p {
        font-size: 0.98rem;
      }

      .key-stat__number {
        font-size: 2.4rem;
      }

      .pull-quote {
        padding: 16px 20px;
      }

      .taper-table th,
      .taper-table td {
        padding: 10px 12px;
        font-size: 0.82rem;
      }
    }
  </style>
</head>
<body>

  <!-- ─── Navigation ────────────────────────────────────────────── -->
  <nav class="nav">
    <a href="/" class="nav__logo">Élan<span>.</span></a>
    <ul class="nav__links">
      <li><a href="/">Home</a></li>
      <li><a href="/blog.html" class="active">Articles</a></li>
      <li><a href="/faq.html">FAQ</a></li>
      <li style="margin-left:8px;border-left:1px solid rgba(197,165,90,0.25);padding-left:16px;"><a href="/et.html" style="font-size:0.7rem;">EST</a></li>
      <li><a href="/#consultation" class="btn" style="padding: 10px 20px; font-size: 0.72rem;">Book a Consultation</a></li>
    </ul>
  </nav>

  <!-- ─── Breadcrumb ────────────────────────────────────────────── -->
  <div class="breadcrumb">
    <div class="container">
      <nav class="breadcrumb__inner" aria-label="Breadcrumb">
        <span class="breadcrumb__item"><a href="/">Home</a></span>
        <span class="breadcrumb__sep">›</span>
        <span class="breadcrumb__item"><a href="/blog.html">Articles</a></span>
        <span class="breadcrumb__sep">›</span>
        <span class="breadcrumb__item breadcrumb__item--current">How to Stop Semaglutide the Right Way</span>
      </nav>
    </div>
  </div>

  <!-- ─── Article Header ───────────────────────────────────────── -->
  <header class="article-header">
    <div class="container">
      <div class="article-header__content">
        <span class="label">GLP-1 Medications · Clinical Protocol</span>
        <h1>How to Stop Semaglutide the Right Way: A Step-Down Protocol</h1>
        <div class="article-meta">
          <div class="article-meta__item">
            <strong>Dr. Ingmar Lindström</strong>
          </div>
          <div class="article-meta__dot"></div>
          <div class="article-meta__item">
            <time datetime="2026-02-28">February 28, 2026</time>
          </div>
          <div class="article-meta__dot"></div>
          <div class="article-meta__item">
            10 min read
          </div>
        </div>
      </div>
    </div>
  </header>

  <!-- ─── Article Body ──────────────────────────────────────────── -->
  <main class="article-body">
    <div class="container">
      <div class="article-body__inner">

        <p>
          Most people stop Ozempic the same way they started it: without a plan.
        </p>

        <p>
          Either cost forced their hand, supply ran out, a doctor suggested "taking a break," or the side effects finally won. Whatever the reason, the exit strategy is usually the same: take the last injection and see what happens.
        </p>

        <p>
          What happens, in most cases, is an appetite rebound that feels unfair. After months of the medication quietly managing hunger in the background, the sudden silence is jarring. The hunger comes back — and for some people, it comes back louder than before treatment.
        </p>

        <div class="pull-quote">
          <p>The Ozempic Aftermath does not have to look this way. If you have any control over how your GLP-1 treatment ends — and often you do — the way you stop matters almost as much as what you do afterward.</p>
        </div>

        <hr />

        <h2>Why stopping abruptly is the harder path</h2>

        <p>
          To understand why tapering matters, it helps to briefly understand what GLP-1 medications are actually doing in your body.
        </p>

        <p>
          Semaglutide and similar drugs work through several mechanisms simultaneously: they suppress ghrelin (the hunger-triggering hormone), slow how quickly the stomach empties after eating, and act on hypothalamic receptors to signal satiety. The net effect is that you eat less, feel fuller faster, and think about food significantly less than you did before.
        </p>

        <p>
          When you stop the medication overnight, all of those mechanisms switch off simultaneously. Your body — which has adapted to the lower appetite environment over months — now receives no GLP-1 signal at all. The result is a sharp, sudden return of hunger signalling. For some people, appetite temporarily overshoots their pre-treatment baseline while the system recalibrates.
        </p>

        <p>
          A gradual taper gives the body time to adjust incrementally. Each dose reduction is a smaller signal change than complete cessation. Hunger returns — it will, eventually, regardless of approach — but more slowly, and at a level that habits have a chance of managing.
        </p>

        <p>
          A 2025 review by the Winnett Specialist Group found that gradual withdrawal protocols were associated with reduced rebound appetite compared to abrupt discontinuation. The evidence base is not enormous — this is a relatively new area of clinical practice — but the mechanism is clear enough that most physicians who think carefully about this recommend tapering when it is feasible.
        </p>

        <hr />

        <h2>Before you start tapering — the checklist</h2>

        <p>
          Tapering without preparation is, as someone once put it to me, like removing a scaffold before the building is finished. The taper buys you time. But what you do with that time determines the outcome.
        </p>

        <p>Before you begin stepping down your dose, these things should be in place — or at least in motion:</p>

        <p>
          <strong>Protein intake established.</strong> Minimum 1.6 grams per kilogram of body weight per day. If you are not there yet, prioritise this above everything else.
        </p>

        <p>
          <strong>Resistance training twice a week.</strong> Not for aesthetics. For metabolic rate. GLP-1 weight loss includes significant lean mass loss — rebuilding and preserving muscle is how you protect your resting metabolism.
        </p>

        <p>
          <strong>Weekly weighing habit.</strong> Same conditions, same time. You need trend data, not noise.
        </p>

        <p>
          <strong>A hunger management strategy.</strong> Structured mealtimes every four to five hours, high-fibre foods at each meal, adequate sleep.
        </p>

        <p>
          <strong>Someone to check in with.</strong> A clinic, a GP, a partner who knows your goals. Isolation during the post-discontinuation period is a risk factor.
        </p>

        <p>
          If several of these are not yet in place, that is information: the taper should be slower, giving you more time to build the habits before the pharmacological support is fully removed.
        </p>

        <hr />

        <h2>The recommended tapering protocol (4–8 weeks)</h2>

        <p>
          This is a general framework for people on weekly injectable semaglutide or tirzepatide. Always discuss changes to your dose schedule with your prescribing physician — individual circumstances vary significantly.
        </p>

        <table class="taper-table">
          <thead>
            <tr>
              <th>Weeks</th>
              <th>Dose</th>
              <th>Purpose</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>1–2</td>
              <td>Current dose (no change)</td>
              <td>Consolidate habits while still fully supported</td>
            </tr>
            <tr>
              <td>3–4</td>
              <td>Half your usual dose</td>
              <td>Begin adjusting to reduced appetite suppression</td>
            </tr>
            <tr>
              <td>5–6</td>
              <td>Quarter dose</td>
              <td>The body starts adapting; hunger returns gradually</td>
            </tr>
            <tr>
              <td>7–8</td>
              <td>Stop</td>
              <td>Discontinuation from a lower baseline — less rebound</td>
            </tr>
          </tbody>
        </table>

        <p>
          The eight-week version is preferable if you have the medication supply to do it. A four-week taper is still significantly better than stopping overnight. Even two weeks of dose reduction before stopping is not nothing.
        </p>

        <p>
          During the taper period, pay attention to hunger patterns. Week three to four is when most people notice a change — portions that felt satisfying at full dose start to feel less so. This is the signal to tighten up meal structure and protein intake. Do not wait until hunger feels unmanageable before adjusting.
        </p>

        <hr />

        <h2>If you have to stop immediately</h2>

        <p>
          Sometimes the taper is not an option. Supply runs out. Cost makes the next injection impossible. A medical situation requires stopping right away. This happens — and it does not mean the outcome is fixed.
        </p>

        <p>
          <strong>Double down on protein and fibre immediately.</strong> Do not wait to see how the hunger develops. Start the dietary adjustments the same week.
        </p>

        <p>
          <strong>Expect two to four weeks of elevated hunger.</strong> This is physiological, not a character flaw. Your body is recalibrating its hunger signalling after months of pharmaceutical suppression. The hunger will not stay at this level indefinitely — it normalises, usually within a month or two, if you are eating structured meals and not feeding the cycle.
        </p>

        <p>
          <strong>Eat on a schedule.</strong> Every four to five hours, with protein at each meal. This dampens the ghrelin spikes that occur when you go long periods without eating.
        </p>

        <p>
          <strong>Track food for 30 days.</strong> The first month after abrupt discontinuation is the period where unconscious eating creep is most likely. Data is your friend here.
        </p>

        <hr />

        <h2>What to expect, week by week</h2>

        <p>
          Understanding the timeline helps. The experience is less frightening when you know what is coming.
        </p>

        <p>
          <strong>Weeks 1–2.</strong> Most people feel relatively little change. Semaglutide has a half-life of approximately one week, meaning the drug is still partially active in your system. Hunger may feel slightly increased but manageable. This window is deceptively calm — use it productively.
        </p>

        <p>
          <strong>Weeks 3–4.</strong> This is when it becomes real. Appetite noticeably returns. Portion sizes that felt satisfying start to feel insufficient. Food thoughts begin to occupy more mental space. If you have a tapering protocol and good habits in place, this is uncomfortable but manageable.
        </p>

        <div class="key-stat">
          <div class="key-stat__number">~Week 8</div>
          <div class="key-stat__label">Weight regain typically begins around week eight post-discontinuation and accelerates through a 20-week peak. Your habits need to be carrying the full load by now. (West et al., BMJ 2026;392:e085304)</div>
        </div>

        <p>
          <strong>Months 3–6.</strong> Appetite generally stabilises. The acute recalibration period is past. People who have built solid habits during the earlier period often report that this phase feels more manageable than they expected. People who did not build those habits typically report that regain has already begun and is difficult to arrest.
        </p>

        <hr />

        <h2>Signs that something needs attention</h2>

        <p>
          Increased hunger is expected. Uncontrollable hunger is a signal worth taking seriously. Here is the distinction:
        </p>

        <div class="warning-box">
          <div class="warning-box__title">Contact your clinic if:</div>
          <p>You are regaining more than 2 kilograms in a four-week period despite following a structured protocol · Hunger feels genuinely unmanageable — not just increased, but overwhelming · Blood sugar is rising (particularly relevant for people with type 2 diabetes) · Mood has deteriorated significantly — GLP-1 receptors exist in the brain as well as the gut, and some people notice mood changes after discontinuation.</p>
        </div>

        <p>
          None of these mean you have failed. They mean the biology is significant enough that additional support is appropriate. That support is available.
        </p>

        <hr />

        <h2>Can you restart later?</h2>

        <p>
          Yes. Clearly and without any medical stigma: restarting GLP-1 therapy after a planned or unplanned break is medically appropriate and well-documented. The body responds to re-initiation similarly to the original treatment course. Dose escalation should follow the same gradual schedule as the first time — starting low and stepping up over weeks — to manage side effects.
        </p>

        <p>
          The idea that GLP-1 use is a one-time window that closes if you stop is not supported by evidence. Obesity is a chronic condition. Intermittent, long-term, or maintenance-dose use of these medications is a legitimate clinical strategy — not a second chance after "failing" to maintain without them.
        </p>

        <p>
          If you are considering restarting, a consultation to review where you are, what habits are in place, and what your goals are is more useful than simply re-initiating without structure. The medication works better when it is part of a plan.
        </p>

        <hr />

        <h2>The bottom line</h2>

        <p>
          How you stop matters. A planned, gradual tapering protocol gives your body time to adjust and gives your habits time to build before the pharmacological support is fully removed. It does not guarantee a perfect outcome — the biology is real, and weight regain is a genuine challenge. But it gives you a meaningfully better starting position for the Ozempic Aftermath.
        </p>

        <p>
          If you are planning to stop in the next one to six months, start preparing now. The best exit strategy is one you begin building before you need it.
        </p>

        <p>
          Also worth reading: <a href="/blog/how-to-keep-weight-off-after-glp1.html">How to Keep the Weight Off After Stopping GLP-1: A Physician's Six-Step Protocol →</a>
        </p>

        <!-- ─── Sources ─────────────────────────────────────────── -->
        <div class="article-sources">
          <span class="sources-label">Sources</span>
          <p>West et al. "Weight regain after discontinuation of GLP-1 receptor agonists: a systematic review and meta-analysis." <em>BMJ</em> 2026;392:e085304.</p>
          <p>Winnett Specialist Group. Gradual withdrawal protocols and rebound appetite in GLP-1 discontinuation. July 2025.</p>
          <p>STEP 1 extension trial. PubMed 35441470.</p>
          <p>EPIC Research, September 2025. Post-discontinuation weight retention data.</p>
          <p><em>This article reflects general clinical guidance and is not a substitute for personalised medical advice. Dose changes should always be discussed with your prescribing physician.</em></p>
        </div>

        <!-- ─── Back Link ──────────────────────────────────────── -->
        <a href="/blog.html" class="back-link">← Back to Articles</a>

      </div>
    </div>
  </main>

  <!-- ─── Footer CTA ────────────────────────────────────────────── -->
  <section class="footer-cta">
    <span class="label">Consultation</span>
    <h2>Planning Your Exit From GLP-1 Therapy?</h2>
    <p class="footer-cta__sub">
      A 45-minute consultation where we build a tapering strategy and post-discontinuation protocol designed to protect the results you have worked for.
    </p>
    <a href="tel:+37252999399" class="btn btn--filled">Call +372 52 99939</a>
  </section>

  <!-- ─── Footer Legal ──────────────────────────────────────────── -->
  <footer class="footer-legal">
    <div class="footer-legal__inner">
      <p>© 2026 Élan Clinic · Elan Clinic OÜ · Reg 17338832 · Medical licence L07470 · Sepapaja 12/1, Tallinn 11415</p>
      <p>This article is for informational purposes only and does not constitute medical advice. Consult your physician before changing any medication or health programme.</p>
    </div>
  </footer>

</body>
</html>
